Skip to main content

Table 1 Characteristics of included studies

From: Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis

Study Year Country No. Cancer type Design Follow-up Cut-off Outcome Treatment HR source NOS
Huang [14] 2019 China 458 (328 [training] + 130 [validation])a Cervical cancer (FIGO stage I, II) R, multi-center 47 m 475 OS, LNM, LVI Surgery M 9
Nie [11] 2019 China 533 (250 [training] + 283 [validation])a Ovarian cancer (FIGO stage I-IV) R, multi-center 46 m 612 OS, PFS, LNM Surgery M 9
Farolfi [15] 2018 Italy 375 Ovarian cancer (FIGO stage III-IV) R, multi-center 43 m 730 OS, PFS Chemotherapy M 7
De Giorgi [16] 2019 USA 516 Breast cancer (triple-negative, HER2+, HER2– ER+) R, single-center 836 OS Systemic treatment Overall (U), subtype (M) 8
Liu [12] 2019 China 160 Triple-negative breast cancer R, single-center 61.7 m 557 OS, DFS Surgery, chemotherapy, radiotherapy M 8
Sun [21] 2019 China 155 Hormone receptor-HER2 + breast cancer R, single-center 57.6 m 578 OS, DFS, LNM Surgery, chemotherapy, radiotherapy M 9
Li [22] 2019 China 161 Luminal breast cancer R, single-center 28.4 m 518 DFS, LNM, LVI Surgery, chemotherapy, radiotherapy, endocrine therapy M 9
Wang [13] 2019 China 215 Triple-negative breast cancer R, single-center 49.2 m 624 OS, DFS, LNM Surgery, chemotherapy, radiotherapy M 9
Holub [20] 2019 Spain 151 Cervical cancer (FIGO stages I–IV) R, single-center 43.8 m 1000 OS Surgery, chemotherapy, radiotherapy U 9
  1. FIGO International Federation of Obstetrics and Gynecology, HER2 epidermal growth factor receptor type 2 ER estrogen receptor, R retrospective, m month, OS overall survival, PFS progression-free survival, DFS disease-free survival, DMFS distant metastasis-free survival, LNM lymph node metastasis, LVI lymphovascular invasion, HR hazard ratio, M multivariate, U univariate
  2. aIncluding the training and validation cohorts